Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    Welcome !
    My account
    Logout

Intersect ENT Inc (XENT) Stock Forecast 2025 - AI Price Prediction & Analysis

Intersect ENT Inc (XENT) AI Stock Price Forecast & Investment Analysis

Intersect ENT Inc Stock Price Chart and Technical Analysis

Loading Intersect ENT Inc interactive price chart and technical analysis...

Intersect ENT Inc (XENT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Intersect ENT Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Intersect ENT Inc, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Intersect ENT Inc: Intersect ENT Inc operates in the Manufacturing sector, making it an emerging small-cap investment.

Intersect ENT Inc (Stock Symbol: XENT) is a leading company in the Manufacturing sector , specifically operating within the Medicinal and Botanical Manufacturing industry.

The organization employs approximately 406 professionals worldwide and operates under the strategic leadership of CEO Thomas West.

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Intersect ENT Inc's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Intersect ENT Inc: With $104M in annual revenue and -161.9% net margin, the company demonstrates developing profitability.

Annual Revenue: $104 million generating a -161.9% net profit margin .

Market Capitalization: $932 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -181.7% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Intersect ENT Inc stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Intersect ENT Inc: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Intersect ENT Inc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Intersect ENT Inc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Intersect ENT Inc: Market positioning analysis based on available financial and operational metrics.

Intersect ENT Inc strategically competes in the highly dynamic Medicinal and Botanical Manufacturing marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 71.9% gross margin, indicating strong pricing power and operational efficiency.

Intersect ENT Inc (XENT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Intersect ENT Inc stock analysis.

Loading Intersect ENT Inc comprehensive fundamental analysis and insider trading data...

Deep dive into Intersect ENT Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Intersect ENT Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Intersect ENT Inc: With a P/E ratio of -5.60, the market sees the stock as potentially undervalued.

P/E Ratio -5.60x
P/B Ratio -10.16x
Market Cap $932M
EPS $-5.04
Book Value/Share $-2.78
Revenue/Share $3.15
FCF/Share $-1.06
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Intersect ENT Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Intersect ENT Inc: An ROE of -181.7% indicates room for improvement in shareholder value creation.

ROE -181.7%
ROA -99.7%
ROIC -55.9%
Gross Margin 71.9%
Operating Margin -75.2%
Net Margin -161.9%
EBT Margin -163.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Intersect ENT Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Intersect ENT Inc: A current ratio of 1.88 shows adequate liquidity.

Current Ratio 1.88x
Quick Ratio 1.38x
D/E Ratio 7.82x
Financial Leverage 14.06x
Interest Coverage -22.8x
Working Capital $74M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Intersect ENT Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Intersect ENT Inc: Free cash flow of $-71M indicates cash challenges that need attention.

Operating Cash Flow $-70M
Free Cash Flow $-71M
Capital Spending $-2M
FCF/Sales -68.5%
CapEx/Sales 1.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Intersect ENT Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Intersect ENT Inc: An asset turnover of 0.62x suggests room for improvement in asset utilization.

Asset Turnover 0.62x
Receivables Turnover 7.5x
Inventory Turnover 1.9x
Fixed Assets Turnover 4.9x
Days Sales Outstanding 49 days
Days Inventory 193 days
Payables Period 101 days
Cash Conversion Cycle 141 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Intersect ENT Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Intersect ENT Inc: With annual revenue of $104M, Intersect ENT Inc demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $104M
Operating Income $-78M
Net Income $-168M
R&D Expense $30M
SG&A Expense $117M
Cost of Goods Sold $28M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 69%
Cash & Short-term Investments 40%
Total Liabilities 174%
Short-term Debt 3%
Accounts Receivable 10%
Inventory 14%
Dividend & Shareholder Information
Shares Outstanding 33M

Latest Intersect ENT Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Intersect ENT Inc (XENT) stock price and investment outlook.

, source: TheStreet.com

Medtronic will acquire all outstanding shares of Intersect ENT for $28.25 a share in an all-cash deal. Medtronic reportedly has offered to buy Intersect ENT, make of drug-delivery devices used by ear, ...

Intersect ENT Inc Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of Intersect ENT Inc against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Intersect ENT Inc Stock Forecast

How accurate are Intersect ENT Inc stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for XENT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Intersect ENT Inc stock price forecasts?

Our analysis considers Intersect ENT Inc's financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Intersect ENT Inc a good investment in 2025?

Based on our AI analysis, Intersect ENT Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Intersect ENT Inc forecasts updated?

Intersect ENT Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Intersect ENT Inc Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Intersect ENT Inc stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...